Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · May 12, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Histologically confirmed advanced or metastatic pleural mesothelioma;
- • 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- • 3. Participants must have previously failed to receive platinum-containing chemotherapy with or without bevacizumab, and have received at most two-line systemic therapy.
- • 4. Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.
- • 5. Adequate haematological, renal and liver function.
- Exclusion Criteria:
- • 1. Primary mesothelioma of peritoneum, pericardium and testes
- • 2. Active, untreated central nervous system (CNS) metastasis.
- • 3. Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.
- • 4. Known active autoimmune diseases.
- • 5. Presence of other uncontrolled serious medical conditions.
About Cancer Institute And Hospital, Chinese Academy Of Medical Sciences
The Cancer Institute and Hospital of the Chinese Academy of Medical Sciences is a leading research and treatment center dedicated to advancing cancer care through innovative clinical trials and comprehensive patient services. As a prominent institution in oncology, it focuses on integrating cutting-edge research with clinical practice, fostering collaborations that enhance the understanding and treatment of various cancer types. The institute is committed to improving patient outcomes by exploring novel therapies, optimizing treatment protocols, and contributing to the global fight against cancer through rigorous scientific investigation and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0